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Abstract
Background: Cisplatin, a platinum based anticancer drug has played a vital role in the treatment
of cancers by chemical agents, but in view of the serious toxicity including nephrotoxicity of
cisplatin, various other platinum based drugs have been synthesized and screened to overcome its
toxicity. A Pt-ATP compound was prepared in our laboratory hoping to have reduced or no
toxicity along with the potentiality of reducing neoplasm growth.
Methods: A Pt-ATP compound was prepared. It was first screened for its antineoplastic efficacy.
Confirming that, subsequent experiments were carried on to test its toxicity on animals, viz. Albino
Swiss mice. The animals were randomly divided into four sets – Set I: Erhlich Ascites Carcinoma (EAC)
challenged mice; Set II: Normal mice; Set III: Drug treated mice, Set IVA Cisplatin (CDDP) treated mice,
Set IV B EAC challenged Cisplatin treated mice. Set I was used to test antineoplasticity of the drug, Set II
and Set III for studying drug toxicity and Set IV was treated with CDDP. Set II was used as a control.
Animals were sacrificed after 5 days, 10 days 15 days and 20 days of drug administration on the 6
th,1 1
th,
16
th and 21
st days respectively for Set I, II and III. Set IVA was sacrificed only on the 16
th day and Set IV
Bo n6
th and 11
th days. For Set I only tumor cell count and packed cell volume (PCV) of tumor cells
were recorded. For Set II and III, aspartate aminotransferase (AST), alanine aminotransferase (ALT)
assays were done using serum while blood creatinine and creatine were assayed from blood filtrate. For
cytotoxicity assessment liver, spleen and kidney tissues were collected and subjected to scanning
electron microscopy (SEM) after extensive treatment. Set IV A was only studied for the biochemical
parameters viz. aspartate aminotransferase (AST), alanine aminotransferase (ALT) assays were done
using serum while blood creatinine and creatine were assayed from blood filtrate. Set IV B was studied
for tumor cell count after treatment with CDDP for 10 days.
Results: Our comparative studies with normal and drug treated animals reveal that the drug does
not affect the body weight of the drug treated animals significantly. The biochemical parameters like
ALT and AST levels are also within normal limits which rules out hepatotoxicity. The detailed
histological studies by SEM reveal that the hepatic, kidney and spleen tissues are not adversely
affected by the drug. Comparison of biochemical parameters with the CDDP treated animals show
Page 1 of 8
(page number not for citation purposes)
BioMed  Central
Open Accessthat Pt-ATP is not at all toxic like the CDDP. The Kaplan-Meier analysis of the survival data of Set I
has shown promising results with a significance of p < 0.0001.
Conclusion: Set I results are promising and indicating antineoplastic efficacy of the synthesized
drug with increased life span of the animals. Biochemical analysis, hematological and SEM studies
revealed that the drug was neither nephrotoxic nor hepato-spleeno-toxic under the experimental
set up.
Background
Neoplasm is any new and abnormal growth; specifically
a new growth of tissue in which the growth is
uncontrolled and progressive. The result is that they
typically pile-up into a non structured mass or tumor.
Neoplasm is of two types: malignant and benign.
Malignant neoplasms are distinguished from benign in
that the former shows a greater degree of anaplasia and
have the properties of invasion and metastasis. This
malignant neoplasm is termed cancer [1]. Cancer, one of
the dreaded diseases of this present time is the cause of
great concern to the modern society.
After the discovery of the anticancer activity of cisplatin
Platinum based drugs have played a vital role in the
treatment of cancers by chemical agents. Cisplatin cis-
diaminedichloroplatinum (II) (DDP) has a wide variety of
application in cancer chemotherapy [2-5]. Although
cisplatin has been found to shrink the tumor burden it
also results in toxicity by decreasing the body weight [6]. It
is also extremely toxic to all fast proliferating normal cells
[7, 8]. The result of chemotherapy by cisplatin has also
been reported to be unsatisfactory due to acquisition of
chemoresistance by tumor cells [9]. Keeping in view the
serious toxicity including nephrotoxicity of these drugs,
various other platinum based drugs have been synthesized
and screened to overcome toxicity of cisplatin [10-13].
ATP and its metal complexes control bioenergetics of
physiological systems. So, we have tried to develop a
novel platinum complex with the natural constituent
ATP hopefully with improved potency and less toxicity
to the hosts. The synthetic complex Pt – ATP has been
shown to demonstrate anticancer activity in experimen-
t a la n i m a lm o d e l[ 1 4 ] .W h e nt r e a t e dw i t ht h ed r u g ,i th a s
been found to decrease the tumor cell count in the
animals challenged with Erhlich Ascites Carcinoma cells
compared to the untreated control group of animals. As
this drug warrants a detailed study on the level of
toxicity, our present investigation emphasizes the study
of toxicity of the drug on normal animals. The results of
our experiments are being presented in the present
communication.
Methods
Animals
Male Swiss albino mice were used for the experiment.
The mice were kept in ventilated cages and maintained
on normal diet and water. The mice were divided into
three sets and challenged with appropriate neoplastic
cell lines to develop neoplasm.
1. Set I – An aliquot of 0.5 ml containing 0.5 × 10
6
Erhlich Ascites Carcinoma (EAC) cells were transplanted
into the peritoneal cavity of Albino Swiss mice and
experiments were carried out. These mice were again
divided into three groups. Set I A – tumor control; Set I B –
low dose drug treated and Set I C – high dose drug
treated.
2. Set II – Normal mice.
3. Set III – Drug treated mice further divided into two
groups: Set III A – Low dose drug treated group and Set
III B – High dose drug treated group.
4. Set IV – Cisplatin cis-dichlorodiammineplatinum (II)
complex treated animals.
Set IV A, only CDDP treated group, Set IV B EAC
challenged mice treated with CDDP.
Preparation of the Pt-ATP compound
The compound (drug) was synthesized following our
earlier methods described previously [15]. K2PtCl4 was
purchased from CDH, India and 5'-adenosine tripho-
sphate disodium salt was purchased from SRL, India. All
other chemicals were AR or GR grade. All glass triple
distilled water was used throughout.
Treatment schedule and experimental design
The compound was dissolved in normal saline (0.9%
NaCl in distilled water, pH = 7.4) immediately before
use and was injected intraperitonially with a dose of 10
mg per kg body weight per day for low dose drug treated
group (Set I B & Set III A) and 20 mg. per kg body weight
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B) for 10 consecutive days. Set IV A animals were treated
with CDDP with a dosage of 10 mg/kg body weight
for 10 consecutive days and animals sacrificed on the
16
th day. Set IV B animals were challenged with EAC
( 0 . 5×1 0
6 cells), treated with 10 mg/Kg body weight of
CDDP and sacrificed on 6
th and 11
th days. Animals were
sacrificed by cardiac puncture under general anesthesia
(GA) using thiopental after 5 days, 10 days 15 days and
20 days of drug administration i.e. on the 6
th,1 1
th,1 6
th
and 21
st days respectively. Tumor cell count and packed
cell volume (PCV) were noted for Set I. For Set II and Set,
III blood was collected by cardiac puncture and serum
extracted from it by centrifugation. Tissues were stored in
2.5% gluteraldehyde at 4°C for scanning electron
microscope (SEM) studies. For Set IVA blood was
collected, serum collected and blood filtrate prepared
as described above after sacrifice of animals. For Set IV B
only tumor cell count was noted.
Tumor cell count
Tumor cell counts were done with the help of
hemocytometer by the use of trypan blue exclusion
method.
PCV estimation
The ascetic fluid was collected after sacrifice from the
peritoneal cavity with the help of a Pasteur pipette. The
peritonial cavity was washed with PBS and the tumor
cells suspended in the PBS. It was then centrifuged at
1500 rpm for 5 minutes at room temperature in a
graduated centrifuge tube. The Cell volume thus pre-
cipitated after centrifugation was recorded.
Anthropometric studies
Body weights of the mice were recorded initially and at
regular intervals of 5 days i.e. on the days of sacrifice.
Weights of the tissues viz. liver, kidney and spleen were
also noted and were expressed as average percentage of
total body weight.
Toxicity studies
Biochemical toxicity assessment
Estimation of aspartate aminotransferase (AST), alanine
aminotransferase (ALT) activity, blood creatinine and
blood creatine were done by following spectrophoto-
metric method [16].
Cytotoxicity assessment
Kidney, liver and spleen were cut into small cubes of
2 mm dimension and fixed in Osmium tetroxide
solution. Those fixed tissues were subjected to CPD
(critical point drying) after extensive dehydration pro-
cess, then gold coated and observed under SEM.
Suvivality studies
Kaplan-Meier curve was drawn for survivality analysis
with the help of MedCalc software [17, 18].
Statistical analyses were done using Microsoft Excel
while images were adapted by Adobe Photoshop.
Results
Set I
The tumor cell counts of the animals bearing EAC cells
with and without drug treatment are noted in Table 1.
Table 2 represents the PCV of Set I animals. Figure 1
represents the Kaplan-Meir curve for survivality analysis
of the Set I animals.
Set II & III
The results of change in body weight of the animals are
presented in Table 3, while the weights of the kidney,
liver and spleen of the animals are presented in Tables 4,
5, and 6 respectively. The weights of the kidney, liver and
spleen are presented as percentage weight of the animals'
body weight for the sake of better comparison.
To ascertain the level of toxicity of the platinum drug, a
detailed biochemical investigation was done. The results
of the biochemical investigation are presented in Table 7
(blood creatinine), Table 8 (blood creatine), and Table 9
(ALT and AST).
Table 1: Total tumor cell count of EAC bearing animals
Time TUMOR
CONTROL (× 10
6)
Dose I*
(× 10
6)
Dose II **
(× 10
6)
Passage 0.5 ± 0.00 0.5 ± 0.00 0.5 ± 0.00
After 5 days 1.0 ± 0.39 0.7 ± 0.16 0.7 ± 0.16
After 10 days 2.2 ± 0.14 1.7 ± 0.07 1.3 ± 0.05
* Dose I = 10 mg per Kg body weight
** Dose II = 20 mg per Kg body weight
Data represented as mean value ± S.D
Table 2: PCV values in mL
# of EAC bearing animals
Time TUMOR
CONTROL
Dose I Dose II
After 5 days 0.01 ± 0 Immeasurable
quantity
Immeasurable
quantity
After 10 days 0.125 ± 0.050 0.0625 ± 0.025 0.125 ± 0.050
N=3 .( m e a n±S . D )
# Measured in μL
Data represented as mean value ± S.D
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extensive histological studies under Scanning Electron
Microscope. The results with each type of tissue in
Normal (without any drug), Low dose and High dose of
drugs are presented with respective captions Figures
( 2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,1 0 ) .
Figure 1
Kaplan-Meier curve of survival data of Set I animals.
Table 3: The average body weight of animals in grams
TIME NORMAL LOW DOSE
DRUG TREATED
HIGH DOSE
DRUG TREATED
Initial 14.9 ± 1.5 19.1 ± 1.6 21.9 ± 2.7
After 5 days 18.4 ± 1.6 21.6 ± 1.9 24.2 ± 5.0
After 10 days 18.3 ± 1.8 20.8 ± 2.5 22.3 ± 4.0
After 15 days 18.5 ± 1.6 19.6 ± 1.9 22 ± 3.1
After 20 days 19.5 ± 1.2 20.6 ± 2.4 23.2 ± 3.8
Data represented as mean value ± S.D
Table 4: The weight of kidney as percentage of total body weight
TIME NORMAL LOW DOSE
DRUG TREATED
HIGH DOSE
DRUG TREATED
After 5 days 1.3 ± 0.4 1.0 ± 0 1.1 ± 0.1
A f t e r1 0d a y s 1 . 0±0 1 . 0±0 1 . 4±0 . 3
A f t e r1 5d a y s 1 . 0±0 1 . 3±0 . 1 1 . 3±0 . 1
A f t e r2 0d a y s 1 . 0±0 1 . 1±0 . 2 1 . 1±0 . 1
Data represented as mean value ± S.D.; n = 3
Table 5: The weight of liver as percentage of total body weight of
the animals.
TIME NORMAL LOW DOSE
DRUG TREATED
HIGH DOSE
DRUG TREATED
After 5 days 4.5 ± 0.7 4.8 ± 0.9 4.9 ± 0.9
After 10 days 5.0 ± 0 5.2 ± 0.7 6.3 ± 0.6
After 15 days 4.5 ± 0.7 5.3 ± 0.5 5.3 ± 0.6
After 20 days 5.9 ± 0.2 4.7 ± 0.8 5.1 ± 0.8
Data represented as mean value ± S.D.; n = 3
Table 6: The weight of spleen as percentage of total body weight
of the animals.
TIME NORMAL LOW DOSE
DRUG TREATED
HIGH DOSE
DRUG TREATED
After 5 days 0.4 ± 0 0.5 ± 0.2 0.3 ± 0.1
After 10 days 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1
After 15 days 0.5 ± 0.1 0.3 ± 0.1 0.5 ± 0.1
After 20 days 0.4 ± 0.1 0.3 ± 0.1 0.4 ± 0.2
Data represented as mean value ± S.D.; n = 3
Table 7: The average values of blood creatinine in mg/dL of
different group of animals.
TIME NORMAL LOW DOSE
DRUG TREATED
HIGH DOSE
DRUG TREATED
After 10 days 0.53 0.29 0.29
After 15 days 0.31 0.33 0.55
After 20 days 0.28 0.18 0.31
Table 8: The average values of blood creatine in mg/dL of
different group of animals.
TIME NORMAL LOW DOSE
DRUG TREATED
HIGH DOSE
DRUG TREATED
After 10 days 1.07 0.76 0.88
After 15 days 0.52 0.52 0.64
After 20 days 1.08 1.08 1.78
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of animals.
TIME NORMAL LOW DOSE
DRUG TREATED
HIGH DOSE
DRUG TREATED
ALT AST ALT AST ALT AST
After 15
days
88.9 71.67 72.2 55.9 67.3 67.6
After 20
days
66.9 100.1 64.2 83.5 64.26 34.7
Figure 2
Scanning electron micrograph of normal hepatocyte.
Figure 3
Scanning electron micrograph of drug treated
hepatocyte (low dose).
Figure 4
Scanning electron micrograph of drug treated
hepatocyte (high dose).
Figure 5
Scanning electron micrograph of normal kidney
medulla.
Figure 6
Scanning electron micrograph of drug treated kidney
medulla (low dose).
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The biochemical parameters of CDDP treated animals
were noted (Table 10) for the comparison of our Pt-ATP
cisplatin analogue with CDDP. Table 11 represents the
tumor cell count of EAC challenged CDDP treated
animals.
Discussions
Our previous preliminary studies indicated that the
synthetic platinum compound Pt-ATP exhibited anti-
neoplastic efficacy in EAC and Sarcoma 180 cells [14].
Set I results (Table 1 and 2) in the present study also
reflect the results of our previous studies. The survivality
analysis with the help of Kaplan-Meier curve (Fig 1)
shows an increase in the survivality of the animals
treated with Pt-ATP which is seen to increase by as much
Figure 7
Scanning electron micrograph of drug treated kidney
medulla (high dose).
Figure 8
Scanning electron micrograph of normal spleen.
Figure 9
Scanning electron micrograph of drug treated spleen
(low dose).
Figure 10
Scanning electron micrograph of drug treated spleen
(high dose).
Table 11: Tumor cell count of CDDP treated animals.
Time TUMOR CONTROL (× 10
6)C D D P t r e a t e d m i c e ( × 1 0
6)
Passage 0.5 ± 0.00 0.5 ± 0.00
After 5
days
1.0 ± 0.39 0.6 ± 0.16
After 10
days
2.2 ± 0.14 1.6 ± 0.15
Table 10: Biochemical parameters of CDDP treated animals.
TIME ALT(I.U) AST(I.U) Blood Creatinine
(mg/dL)
Blood Creatine
(mg/dL)
After
15 days
110.9 184.5 13.01 16.05
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in case of Set IB animals. The significance of level is
p < 0.0001 according to the Chi Square test. The control
group (Set I) is seen to die within 20 days whereas the
treated groups remain alive for 45 days and more. As a
number of platinum drugs are known to impart high
level of toxicity on the drug treated hosts, the develop-
ment of anticancer platinum drugs with lower degree of
toxicity continued. We also synthesized the said Pt-ATP
drug with a naturally occurring ligand ATP considering
that this may be less toxic to the hosts. So, in this work
we have undertaken a detailed investigation on the toxic
levels. Our comparative studies with normal and drug
treated animals reveal that the drug does not affect the
body weight of the drug treated animals significantly.
Many anticancer drugs are known to affect the kidney,
liver and spleen adversely, so we have undertaken studies
by monitoring the relative weights of these drug treated
organs with normal ones and found that they are very
much within normal limits in the drug treated groups.
The biochemical parameters like ALT and AST levels are
also within normal limits which rule out hepatotoxicity.
The normal levels of blood creatinine and blood creatine
indicate that the drug does not impart any adverse effect
on the kidney of the hosts. The detailed histological
studies by SEM reveal that the hepatic cells are not
adversely affected by the drug (Figs 3, 4). The kidney
medullas are visualized with distinct clarity (Figs 6, 7)
which indicates that the drug is not nephrotoxic either.
The spleenic cellularity has clearly been demonstrated in
the drug treated animals both at higher and lower dose
of the drug (Figs 9, 10). Set IV A results (Table 10) clearly
depict an increase in serum AST and ALT levels indicating
hepatotoxicity to a mild extent. It also shows a dramatic
increase in blood creatine and creatinine values indicat-
ing nephrotoxicity. Thus, even though the Set IV B results
represent a pleasant picture with the antitumor activity
but due to its serious toxic effects, its use as an anticancer
drug needs reviewing. In comparison to our results of Set
II and Set III, CDDP appears to be toxic to the animals.
Our above studies reveal that this drug does not induce
any apparent toxicity on the treated hosts and seems to
be a promising drug in the management of cancer under
the present experimental set up.
Further studies both with respect to toxicity and dose
response activity in cancerous animals are underway in
our laboratory.
Conclusion
The results of Set I clearly establishes the antineoplastic
efficacy of the synthesized Pt – ATP drug. The biochem-
ical analysis of the ALT, AST, blood creatinine and blood
creatine levels reveal that the above values are within the
normal range. SEM observation shows normal cell
morphology of the tissues of all groups. Results of Set
IV also show that although CDDP is an effective
anticancer drug it has serious toxic effects on the hosts.
This study suggests that the present drug, the Pt-ATP
neither being hepato-spleeno-toxic nor nephrotoxic at
the present experimental set up has a bright prospect for
future studies.
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